目的 探討苓桂咳喘寧膠囊聯(lián)合茶堿緩釋片治療哮喘急性發(fā)作的臨床效果。方法 選取2021年1月—2021年12月亳州市人民醫(yī)院收治的100例哮喘急性發(fā)作患者，按隨機(jī)數(shù)字表法分為對照組與治療組，每組各50例。對照組口服茶堿緩釋片，1片/次，2次/d。治療組在對照組基礎(chǔ)上口服苓桂咳喘寧膠囊，5粒/次，3次/d。兩組均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組治療前后肺通氣功能指標(biāo)、哮喘生命質(zhì)量問卷（AQLQ）評分及相關(guān)炎癥指標(biāo)水平。結(jié)果 治療后，治療組總有效率是96.0%，較對照組的84.0%顯著提高（P<0.05）。治療后，治療組咳嗽、氣促、胸悶、喘息和肺部哮鳴音等典型表現(xiàn)的消失時間較對照組均顯著縮短（P<0.05）。治療后，兩組第1秒用力呼氣容積（FEV₁）占預(yù)計值%顯著高于治療前，而呼氣峰流速（PEF）晝夜變異率低于治療前（P<0.05）；但均以治療組的改善更顯著（P<0.05）。治療后，兩組AQLQ中癥狀、情感功能、活動受限、環(huán)境刺激評分及其總分均顯著高于治療前（P<0.05）；但治療后，治療組AQLQ中各能區(qū)評分及其總分的提高作用較對照組更顯著（P<0.05）。與治療前相比，兩組患者治療后外周血嗜酸性粒細(xì)胞（EOS）計數(shù)、呼出氣一氧化氮（FeNO）、白細(xì)胞介素（IL）-6水平均顯著下降（P<0.05）；且治療組患者外周血EOS計數(shù)、FeNO及血清IL-6水平低于對照組（P<0.05）。結(jié)論 苓桂咳喘寧膠囊與茶堿緩釋片聯(lián)合治療哮喘急性發(fā)作的效果確切，是緩解患者哮喘癥狀、改善氣流受限及提高生活質(zhì)量的安全有效方案，并能進(jìn)一步緩解患者體內(nèi)炎癥反應(yīng)，有利于控制病情。

Objective To investigate the clinical effect of Linggui Kechuanning Capsules combined with Theophylline Sustained-release Tablets in treatment of acute asthma attack. Methods A total of 100 patients with acute asthma attack admitted to Bozhou People's Hospital from January 2021 to December 2021 were selected and divided into control group and treatment group according to random number table method, with 50 cases in each group. Patients in the control group were po administered with Theophylline Sustained-release Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Linggui Kechuanning Capsules on the basis of the control group, 5 grains/time, three times daily. Both groups were treated for 14 d. The clinical efficacy of the two groups were observed, and the levels of pulmonary ventilation function indexes, asthma quality of life questionnaire (AQLQ) score and related inflammatory indexes were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 96.0%, significantly higher than that of the control group (84.0%) (P < 0.05). After treatment, the disappearance time of typical symptoms such as cough, shortness of breath, chest tightness, wheezing and pulmonary wheezing in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the proportion of FEV1% in both groups was significantly higher than before treatment, while the diurnal variation rate of PEF was lower than before treatment (P < 0.05). However, the improvement in treatment group was more significant (P< 0.05). After treatment, AQLQ symptoms, affective function, activity limitation, environmental stimulus score and total score in two groups were significantly higher than before treatment (P < 0.05). However, after treatment, AQLQ scores and total scores in the treatment group were more significant than those in the control group (P < 0.05). Compared with before treatment, eosinophil (EOS) count, nitric oxide (FeNO) and interleukin (IL-6) levels in peripheral blood of two groups were significantly decreased after treatment (P < 0.05). After treatment, the treatment group had more significant effect on the decrease of EOS count in peripheral blood, FeNO and serum IL-6 levels than the control group (P < 0.05). Conclusion Linggui Kechuanning Capsules combined with Theophylline Sustained-release Tablets has accurate effect in treatment of acute asthma attack, and is a safe and effective solution to relieve asthma symptoms, improve airflow limitation and improve life quality, and can further alleviate the inflammatory response in patients, which helps to control the disease.

R974

亳州市科技局科研項目（1604a0802091）